Device Trial Radar · NCT05821465
Ambulatory Leadless Electrocardiogram Recorder Trial Feasibility
Last checked: Nov 20, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
144
Actual
Start
Jul 1, 2023
Primary completion
Jul 18, 2024
Study completion Jul 18, 2024
Sponsor
- Lead sponsor
- HelpWear Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Apr 20, 2023
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 22 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to compare the heart signals that are received by a new heart monitoring device called the HeartWatch to heart signals that are recorded by existing monitors used in cardiology clinics today. The main question\[s\] it aims to answer are: 1. Does the HeartWatch recording allow characterization of tagged and abnormal arrhythmia events that are equivalent to the existing Event Recorder and Holter devices? 2. Does the HeartWatch recording allow for detection of QRS complexes that are equivalent to the predicate Holter lead I reference signal? Participants who have been recommended to receive a heart monitor for heart rhythm assessment will asked to wear the HeartWatch armband monitor at the same time as the standard heart monitor. They will be asked to flag symptoms (if they occur) on either the HeartWatch or on the Helpwear Smartphone. When their monitoring session for the standard heart monitor is complete, then the monitoring session for the HeartWatch armband is also complete.
Conditions
- Arrhythmias, Cardiac
- Palpitation
- Syncope
- Light Headedness
Interventions
HeartWatchDevice
The HeartWatch monitoring device will be worn on the upper left arm for the same duration or up to 48 hours that the standard event recorder or holter monitor is worn. The subject will be provided with a HelpWear smartphone that is paired to the monitor and only used by the participant to tag any events that they may have during the Heartwatch monitoring session.
Primary outcomes
What the sponsor says the trial is designed to measure.
- HeartWatch arrhythmia event characterization accuracyTime frame: Events will be assessed for the duration of time each participants wears the HeartWatch and holter/event recorder, up to 48 hours.
- HeartWatch recording accuracy of QRS complexesTime frame: QRS complexes will be assessed for the duration of time each participants wears the HeartWatch and the holter monitor up to 48 hours.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Foothills Medical Centre
Calgary, Alberta, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.